Merck & Co., Inc. (MRK)
150.33
-2.01
(-1.32%)
USD |
NYSE |
Sep 04, 16:00
150.51
+0.18
(+0.12%)
Pre-Market: 20:00
Merck Research and Development Expense (Quarterly) : 9.229B for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 9.229B |
| March 31, 2026 | 11.98B |
| December 31, 2025 | 2.499B |
| September 30, 2025 | 3.552B |
| June 30, 2025 | 3.54B |
| March 31, 2025 | 3.119B |
| December 31, 2024 | 4.052B |
| September 30, 2024 | 5.309B |
| June 30, 2024 | 2.886B |
| March 31, 2024 | 3.479B |
| December 31, 2023 | 9.126B |
| September 30, 2023 | 2.855B |
| June 30, 2023 | 12.89B |
| March 31, 2023 | 3.828B |
| December 31, 2022 | 2.962B |
| September 30, 2022 | 3.511B |
| June 30, 2022 | 2.776B |
| March 31, 2022 | 2.569B |
| December 31, 2021 | 2.751B |
| September 30, 2021 | 2.437B |
| June 30, 2021 | 2.615B |
| March 31, 2021 | 2.405B |
| December 31, 2020 | 2.438B |
| September 30, 2020 | 2.476B |
| June 30, 2020 | 2.054B |
| Date | Value |
|---|---|
| March 31, 2020 | 2.159B |
| December 31, 2019 | 2.362B |
| September 30, 2019 | 2.223B |
| June 30, 2019 | 2.184B |
| March 31, 2019 | 1.895B |
| December 31, 2018 | 2.061B |
| September 30, 2018 | 2.072B |
| June 30, 2018 | 2.271B |
| March 31, 2018 | 3.194B |
| December 31, 2017 | 1.831B |
| September 30, 2017 | 4.166B |
| June 30, 2017 | 1.773B |
| March 31, 2017 | 1.737B |
| December 31, 2016 | 887.00M |
| September 30, 2016 | 1.635B |
| June 30, 2016 | 1.883B |
| March 31, 2016 | 1.569B |
| December 31, 2015 | 1.794B |
| September 30, 2015 | 1.482B |
| June 30, 2015 | 1.584B |
| March 31, 2015 | 1.674B |
| December 31, 2014 | 1.846B |
| September 30, 2014 | 1.542B |
| June 30, 2014 | 1.621B |
| March 31, 2014 | 1.493B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Johnson & Johnson | 3.603B |
| Eli Lilly & Co. | 3.819B |
| Pfizer Inc. | 2.746B |
| Bristol Myers Squibb Co. | 2.316B |
| Abbott Laboratories | 892.00M |